Podcasts

Julie Gralow, MD, Clinical Director at the Seattle Cancer Care Alliance, discusses findings from the SWOG S0307 trial.

Ezzat Elhassadi, MD, discusses the impact of a p53 alteration in patients with MCL; these data were presented at the EHA2021 Virtual Congress.

Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.

Peter Martin, MD, discusses various treatment patterns and outcomes of patients with MCL over the past 10 years; these data were presented at the 2021 ASCO Annual Meeting.

Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.

Dr Shah discusses his research on the use of a bi-specific anti-CD20/CD19 CAR-T therapy for patients with B-cell NHL or CLL.

Nakia Spencer, MSc, discusses the ongoing trial of asparagine synthetase (ASNS) expression to predict patient response to the GLS1 inhibitor IPN60090 in ovarian cancer.

Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer, an approval based on results following the DESTINY-Gastric01 study.

Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.